Anti-Human HLA-DR/DP/DQ Antibody (Clone: F3.3) | PA007460

Catalog No.	PA007460
Product Name	In vivo Grade Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody, Mouse IgG1 Kappa (Clone: F3.3)
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	beta1 domain MHC class II HLA DPB, CELIAC1, class II HLA beta chain, MHC class II HLA-DR, DP, DQ
Clone	F3.3.
Isotype	Mouse IgG1 Kappa.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: F3.3) specifically binds to mouse HLA-DR/DP/DQ.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse HLA-DR/DP/DQ protein.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The in vivo grade recombinant anti-human HLA-DR/DP/DQ antibodies (clone of F3.3) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant Mouse IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007460: Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody (Clone: F3.3), Mouse IgG1 Kappa, In vivo Grade

The in vivo grade recombinant anti-human HLA-DR/DP/DQ Mouse IgG1 Kappa monoclonal antibody was produced in mammalian cells.

References of Anti-Human HLA-DR/DP/DQ Monoclonal Antibody (Clone: F3.3)

1. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling
de Haij, S., et al.Cancer Res. 2010 Apr 15;70(8):3209-17. doi: 10.1158/0008-5472.CAN-09-2869. PMID: 20354182
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was used as a control for HLA class II binding in in vivo experiments, showing no significant cytotoxicity without ITAM signaling. In vivo depletion studies in mouse models confirmed that neutrophils armed with F3.3 bispecific constructs mediated tumor clearance, highlighting the critical role of Fc receptor signaling in antibody-mediated efficacy.”

2. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Dechant, M., et al.Blood. 2002 Dec 15;100(13):4574-80. doi: 10.1182/blood-2002-03-0687. PMID: 12393717
“Chimeric F3.3 antibodies (anti-human HLA-DR/DP/DQ), including human IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 isotypes, were generated using variable regions from the F3.3 hybridoma (GenBank AY058910 [V L], AY058911 [V H]). Saturating concentrations showed similar binding to HLA class II-transfected L66 cells via indirect immunofluorescence, confirming effective lymphoma cell killing across isotypes.”

3. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells
Stockmeyer, B., et al.Cancer Res. 1998 Jul 15;58(14):3051-4. PMID: 9679970
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was tested for its ability to induce polymorphonuclear neutrophil (PMN)-mediated lysis in in vivo mouse models. HLA class II antibodies, including F3.3, consistently mediated high levels of target cell killing. In vivo experiments showed enhanced tumor regression with F3.3, and bispecific [HLA class II x FcyRI] antibodies significantly improved survival in lymphoma-bearing mice.”

4. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies
Heijnen, I. A., et al.J Immunol. 1997 Dec 1;159(11):5629-35. PMID: 9548506
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was used with granulocyte colony-stimulating factor (G-CSF) to arm neutrophils in vivo, enhancing tumor cell killing. The combination of G-CSF and F3.3 bispecific antibodies led to specific cytotoxicity against HER-2/neu-expressing cells, demonstrating efficient neutrophil recruitment and activation in mouse models.”

5. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
Stockmeyer, B., et al.Blood. 1996 May 1;87(9):3803-12. doi: 10.1182/blood.V87.9.3803.bloodjournal8793803. PMID: 8611706
“HLA class II antibodies, including F3.3 (anti-human HLA-DR/DP/DQ), mediated significant cytotoxicity with neutrophils from healthy donors and G-CSF-treated patients against B-cell lines. Bispecific antibodies, such as [HLA class II x FcyRI] and [HLA class II x FcyRII], cross-linked with F3.3 F(ab’) fragments, achieved 15.7–33.9% specific lysis of RAJI cells at 10 pg/mL, demonstrating effective targeting of malignant B cells.”

For more technical references or data sheets regarding the Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody (Clone: F3.3) formats, please contact our scientific support team at message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
recombinant mouse IgG1 isotype control antibody, In vivo grade

Anti-Human HLA-DR/DP/DQ (F3.3) from: Anti-Human HLA-DR/DP/DQ Monoclonal Antibody, Mouse IgG1 Kappa (Clone: F3.3): PA007460 Syd Labs